Biomarin

What Does 2016 Hold for Biotech Stocks?
Motley Fool
Sun, 01/3/16 - 10:27 pm
biotech
Gilead Sciences
Celgene
Amgen
Regeneron
Sanofi
Biomarin
Sarepta Th
How Gilead Sciences M&A Can Pan Out Next Year
Bidness, ETC
Tue, 12/29/15 - 09:36 am
Gilead Sciences
M&A
Vertex Pharmaceuticals
Incyte
Biomarin
Regeneron
BioMarin Announces That FDA Has Advised it Will Not Take Action on the Kyndrisa™ (drisapersen) New Drug Application by the PDUFA Date
Yahoo
Fri, 12/18/15 - 09:07 am
Biomarin
FDA
drisapersen
Kyndrisa
Duchenne Muscular Dystrophy
FDA Committee Raises Concerns about Kyndrisa’s Efficacy, Safety
Yahoo/Market Realist
Fri, 12/11/15 - 10:27 pm
FDA
Kyndrisa
Duchenne Muscular Dystrophy
Biomarin
drisapersen
BioMarin: So You’re Saying There’s a Chance?
Barron's
Wed, 11/25/15 - 11:31 am
Biomarin
Duchenne Muscular Dystrophy
drisapersen
Kyndrisa
FDA
BioMarin Duchenne drug appears destined for failure after brutal FDA meeting
BioPharma Dive
Wed, 11/25/15 - 10:53 am
Biomarin
Duchenne Muscular Dystrophy
FDA
advisory panels
drisapersen
​The first drug for Duchenne will be reviewed at the FDA today: Why it matters
Bizjournals.com
Tue, 11/24/15 - 09:51 am
FDA
Biomarin
advisory panels
Duchenne Muscular Dystrophy
Kyndrisa
drisapersen
BioMarin FDA Panel Live Blog
TheStreet.com
Tue, 11/24/15 - 09:06 am
Biomarin
FDA
advisory panels
Duchenne Muscular Dystrophy
drisapersen
Duchenne moms say FDA documents ‘widen the divide’ between drugs by BioMarin, Sarepta
Bizjournals.com
Fri, 11/20/15 - 06:19 pm
Duchenne Muscular Dystrophy
FDA
eterplirsen
drisapersen
Biomarin
Sarepta Therapeutics
FDA staff unveils strongly critical review of BioMarin Duchenne drug ahead of crucial meeting
BioPharma Dive
Fri, 11/20/15 - 11:11 am
FDA
Biomarin
Duchenne Muscular Dystrophy
drisapersen
Experts say Sarepta has a clear edge over BioMarin in Duchenne drug battle
Bizjournals.com
Thu, 11/5/15 - 12:47 pm
Sarepta Therapeutics
Biomarin
Duchenne Muscular Dystrophy
eteplirsen
drisapersen
FDA ‘Weirdness?’ Separate meetings for BioMarin and Sarepta DMD drugs
Pharmalot
Thu, 10/15/15 - 03:59 pm
FDA
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
drisapersen
​Sarepta’s competitor on Duchenne drug could get a two-month head start on sales
Bizjournals.com
Wed, 10/14/15 - 02:23 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biomarin
eteplirsen
drisapersen
Sarepta Therapeutics vs. BioMarin Pharmaceutical: Which Company Will Win the DMD Race?
Motley Fool
Tue, 10/6/15 - 07:13 pm
Sarepta Therapeutics
Biomarin
Duchenne Muscular Dystrophy
eteplirsen
drisapersen
What It's Like To Have Dinner With BioMarin Executives
Yahoo/Benzinga
Wed, 09/16/15 - 06:12 pm
Biomarin
Sarepta snags priority review status to keep pace with BioMarin in DMD race
Fierce Biotech
Wed, 08/26/15 - 09:28 am
Sarepta Therapeutics
priority review
Duchenne Muscular Dystrophy
FDA
eteplirsen
drisapersen
Biomarin
Why BioMarin hawked a phase III cancer drug to Medivation for $570M
BioPharma Dive
Wed, 08/26/15 - 08:47 am
Biomarin
Medivation
BMN 673
Sarepta, Biomarin vie for DMD approval, priority review voucher
BioPharma Dive
Mon, 08/24/15 - 11:47 am
Sarepta
Biomarin
Duchenne Muscular Dystrophy
FDA
priority review
review vouchers
BioMarin sells its PhIII cancer drug to Medivation for $570M
Fierce Biotech
Mon, 08/24/15 - 11:22 am
Biomarin
Medivation
talazoparib
breast cancer
BRCA1
BRCA2
BioMarin's Big Bet on Muscular Dystrophy Is Already Paying Off
Motley Fool
Sat, 08/22/15 - 09:01 am
Biomarin
Duchenne Muscular Dystrophy
drisapersen

Pages